Abstract: Muscular dystrophies, including Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy (BMD), are severe genetic disorders characterized by progressive muscle degeneration due to mutations in the dystrophin gene. The loss of functional dystrophin triggers a cascade of secondary pathological events, notably the constitutive hyperactivity of histone deacetylases (HDACs), which drives chronic inflammation, fibrosis, and impaired muscle regeneration. Givinostat (ITF-2357) is an orally bioavailable, hydroxamate-based pan-HDAC inhibitor that has emerged as a promising therapeutic agent to halt this pathological cascade. By promoting histone hyperacetylation, givinostat restores the expression of myogenic genes, modulates microRNA profiles, and redirects fibro-adipogenic progenitors (FAPs) away from fibrotic lineages toward supporting myogenesis. Recently approved by the FDA for the treatment of DMD, givinostat is also currently under clinical investigation for Becker muscular dystrophy. This review synthesizes the pharmacological activity, molecular mechanisms, limitations, and future perspectives of givinostat in the context of muscular dystrophies, based on recent literature.
1. Introduction
Muscular dystrophies (MDs) represent a heterogeneous group of genetic disorders characterized by progressive weakness and degeneration of skeletal muscles [2]. The most common and severe forms, Duchenne muscular dystrophy (DMD) and the related Becker muscular dystrophy (BMD), are caused by mutations in the DMD gene encoding the protein dystrophin [1][2]. Dystrophin plays a critical structural role by anchoring the cytoskeleton to the extracellular matrix via the dystrophin-associated protein complex (DAPC), providing mechanical stability to muscle fibers during contraction [1][2].
The absence or dysfunction of dystrophin leads to sarcolemma instability, calcium imbalance, and the displacement of signaling molecules such as neuronal nitric oxide synthase (nNOS) [1][2][4]. This disruption results in a secondary pathological cascade marked by chronic inflammation, oxidative stress, defective autophagy, and the replacement of muscle tissue with fibrotic scar tissue and fat [1][4]. A key driver of this secondary pathology is the aberrant, constitutive hyperactivation of histone deacetylases (HDACs) [1]. Consequently, pharmacological blockade of HDACs has been heavily investigated. Givinostat (ITF-2357) is a potent pan-HDAC inhibitor that has demonstrated the ability to counteract muscle degeneration and is now FDA-approved for DMD, with ongoing clinical evaluation for Becker muscular dystrophy [1][2][3].
2. Pharmacological Activity
Givinostat exhibits broad pharmacological activity aimed at restoring muscle homeostasis and slowing disease progression in dystrophic models. In preclinical studies using mdx mice (a model for dystrophinopathy), givinostat treatment resulted in significant functional and histological improvements. It increased muscle fiber diameter (cross-sectional area), improved muscle strength in grip tests, and enhanced endurance in treadmill exhaustion tests [1]. Furthermore, givinostat significantly reduced muscle fibrosis by up to 30%–40% and decreased fat replacement and tissue necrosis [1][2].
Beyond structural improvements, givinostat acts as a metabolic remodeling agent. It promotes the recovery of mitochondrial biogenesis and induces an oxidative fiber-type switch in dystrophic muscles by increasing the expression of PGC-1α, a key regulator of mitochondrial metabolism [2]. It also exhibits potent anti-inflammatory effects, evidenced by a transient reduction in the in vitro production of pro-inflammatory cytokines and significantly reduced myeloperoxidase (MPO) activity (a marker of neutrophil and macrophage infiltration) in treated muscles [1].
Clinically, givinostat has shown efficacy in slowing disease progression. In a Phase 3 placebo-controlled trial for DMD, 18 months of givinostat treatment significantly improved muscle function, slowed muscle degeneration, and reduced fat infiltration in the vastus lateralis by 30% [1]. Building on these encouraging results, a Phase II clinical study of givinostat specifically for the treatment of Becker muscular dystrophy was initiated in 2017 to evaluate its efficacy in this related patient population [2].
3. Molecular Mechanism of Action
The primary mechanism of action of givinostat involves the global inhibition of HDAC enzymes. In dystrophic muscles, hyperactive HDACs remove acetyl groups from histones, leading to a "closed" chromatin structure that represses the transcription of key homeostatic and muscle repair genes [1]. Givinostat reverses this by inducing histone hyperacetylation, resulting in a relaxed chromatin state that allows transcription factors to access DNA and enhance the expression of genes involved in myogenesis and anti-inflammatory responses [1].
At the cellular level, givinostat profoundly affects fibro-adipogenic progenitors (FAPs). In dystrophic environments, FAPs typically differentiate into fibroblasts and adipocytes, driving fibrosis and fat accumulation. Givinostat redirects the lineage commitment of FAPs toward a pro-myogenic phenotype [2]. It achieves this by modulating the microRNA (miRNA) cargo of extracellular vesicles released by FAPs. Givinostat upregulates pro-myogenic miRNAs (such as miR-1.2, miR-133, and miR-206) which repress the BAF60A and BAF60B variants of the SWI/SNF chromatin remodeling complex, favoring the BAF60C variant that activates muscle gene transcription [1][2].
Additionally, givinostat impacts non-histone proteins. For instance, HDAC inhibition prevents the deacetylation of SMAD proteins, thereby dampening TGF-β signaling and reducing fibrogenesis [1]. Furthermore, HDAC inhibitors like givinostat help restore autophagic flux, which is typically suppressed in dystrophic muscle due to Akt-mTOR hyperactivation, thereby aiding in the clearance of damaged organelles and toxic protein aggregates [4].
4. Structure-Activity Relationship (SAR)
While exhaustive structure-activity relationship (SAR) data for givinostat derivatives are not detailed in the provided literature, givinostat (ITF-2357) is identified chemically as a hydroxamate-based compound [2]. The hydroxamic acid moiety is a classic zinc-binding group that chelates the zinc ion located in the catalytic pocket of zinc-dependent HDACs (Classes I, II, and IV) [3]. As a pan-HDAC inhibitor, givinostat broadly targets multiple HDAC isoforms. Notably, unlike many other HDAC inhibitors that possess a very narrow therapeutic window and dose-limiting toxicities, the specific structural profile of givinostat allows it to achieve potent HDAC inhibition and clinical efficacy at dosing levels that are generally well-tolerated by pediatric and adult patients [1].
5. Current Limitations
Despite its therapeutic promise, the use of givinostat and other pan-HDAC inhibitors is accompanied by several limitations:
- Adverse Events: Pan-HDAC inhibitors are associated with common side effects. For givinostat, clinical trials have reported monitorable gastrointestinal symptoms (such as diarrhea), anorexia, nausea, vomiting, thrombocytopenia, and hypertriglyceridemia, which generally require dose adjustments for management [1][2].
- Lack of Isoform Specificity: Because givinostat is a pan-HDAC inhibitor, it blocks numerous HDAC family members across different classes. Given the specific and sometimes redundant roles of different HDAC isoforms in various tissues, this broad inhibition can lead to unwanted off-target side effects [2].
- Stage-Dependent Efficacy: Preclinical evidence suggests that the beneficial effects of HDAC inhibitors rely heavily on the presence of an active muscle regeneration window. If treatment is initiated at late stages of the disease when the muscle stem cell regenerative potential is exhausted and FAPs have entered a senescent state, the compound loses its beneficial effects on muscle regeneration [2].
6. Future Perspectives
The future of givinostat and HDAC inhibition in muscular dystrophies like BMD and DMD points toward combination therapies and refined targeting:
- Combination Therapies: Because givinostat works independently of specific genetic mutations to improve muscle quality, it is an ideal candidate for combination with dystrophin-restoring treatments (e.g., exon skipping or micro-dystrophin gene therapy). Since these genetic therapies rely on the presence of viable muscle tissue, givinostat's ability to preserve muscle mass and reduce fibrosis is expected to provide synergistic benefits [1]. Preclinical models have already shown that combining givinostat with exon-skipping compounds increases dystrophin transcript and protein levels more than exon skipping alone [1].
- Isoform-Specific Inhibitors: To circumvent the side effects of pan-HDAC inhibition, future research is heavily focused on developing isoform-specific inhibitors. For example, selective inhibition of HDAC6, HDAC8, or HDAC11 has shown preclinical promise in reducing inflammation, restoring autophagy, and accelerating muscle regeneration without the broad epigenetic disruption caused by pan-inhibitors [2][3][4].
- Expanded Clinical Indications: The ongoing Phase II clinical trials of givinostat for Becker muscular dystrophy will provide critical data on its long-term safety and efficacy in this specific population, potentially expanding its regulatory approval beyond DMD [2].
